



**Lakeridge  
Health**

---

CLINICAL TRAILS



## CLINICAL TRAILS

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim

[Start Research](#)



Choose a research study:

Lung Trails



Condition:

Small Cell (SCLC)



Other Term

Limited



FIND ELIGIBLE STUDY



## Results



Open to  
Recruitment




Closed to  
Recruitment

## Patient not eligible to clinical studies

*For more detail information please contact*

Lorem ipsum  
(905) -123 - 4567 EXT. 123  
123 Bloor St. W, ON L2E 4G5  
sample.email@gmail.com  
websiteaddress.ca





[About](#) > [Trails](#) >

Choose a research study:

Lung Trails



Condition:

Small Cell (SCLC)



Other Term


Extensive



Maintenance



Over 70 years



Under 70 years

FIND ELIGIBLE STUDY





## Results



Open to  
Recruitment



Closed to  
Recruitment

## Patient eligible to the following studies:

**(ABBVIE) M16-298 / MERU) RN: Marianna**

[VIEW DETAILS](#)

*(BMS) CA209907: An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants with Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed  
During or After Receiving at Least One Prior Systemic Regimen*

**BASKET STUDY**

[VIEW DETAILS](#)





Choose a research study:

Lung Trials



Condition:

Non-small Cell (NSLSC)



Other Term

Resectable



**Adjuvant Therapy**



Over 70 years



Under 70 years

**FIND ELIGIBLE STUDY**





## Results



Open to  
Recruitment



Closed to  
Recruitment

## Patient eligible to the following studies:

**(CCTG) BR.31: RN: Marianna**

[VIEW DETAILS](#)

*A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer*

**BASKET STUDY**

[VIEW DETAILS](#)





Choose a research study:

Lung Trials



Condition:

Non-small Cell (NSLSC)




Other Term

Unresectable



Second Line



Over 70 years



Under 70 years

**FIND ELIGIBLE STUDY**





## Results



Open to  
Recruitment



Closed to  
Recruitment

## Patient eligible to the following studies:

### BMS CA209-907

[VIEW DETAILS](#)

*(BMS) CA209907: An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants with Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen*





Choose a research study:

Lung Trials


Condition:

Non-small Cell (NSLSC)


Other Term

Unresectable

Second Line



Over 70 years



Under 70 years

FIND ELIGIBLE STUDY

ABOUT

---

FIND TRAILS

---

CONTACT

